Objective: The goal of this study was to evaluate the accuracy and safety of ultrasound- guided
tru-cut biopsy in patients with either primarily inoperable pelvic tumor, advanced
tumor and compromised performance status, or recurrent pelvic tumor.
Methods: Consecutive patients referred in the Center for minimally invasive biopsy from Jan
2005 to Dec 2006 were included in the study. The tissue samples were obtained using
an automatic bioptic gun (Fast Gun, Sterylab, Italy) in combination with a disposable
tru-cut needle (Fast Cut Needle, Sterylab, Italy, 16G/250mm for transvaginal and 14–16
G/150–200mm for transabdominal biopsy) guided by ultrasound.
Results: Together 90 patients were enrolled and only 4 were not suitable for biopsy. The biopsy
was taken either from pelvic tumor (54.6%), peritoneal metastases (31.4%), or omental
cake (14%). Samples were obtained transvaginally (53.5%) or transabdominally (46.5%).
A diagnosis consistent with primary ovarian malignancy was made in 62.8%, metastatic
ovarian involvement was found in 10.5%, and extraovarian tumor in 26.7%. The diagnostic
accuracy of ultrasound guided tru-cut biopsy reached 97.7%. There was only one complication,
a bleeding from tumor in the patient with mild thrombocytopenia due to metastatic
infiltration of bone marrow, requiring laparotomy.
Conclusion: Ultrasound-guided tru-cut biopsy is safe, reliable and cost-effective method. It can
be performed in an outpatient setting without a need of general anesthesia and provides
an adequate specimen for histological analysis including immunohistochemical methods.
It should, therefore, be considered as a method of choice for histological verification
of both advanced primary and recurrent pelvic tumors.